Valuation: Addex Therapeutics Ltd

Market Cap 4.58M 5.59M 5.01M 4.18M 7.89M 525M 8.13M 55.27M 22.13M 280M 20.98M 20.53M 885M P/E 2024
0.8x
P/E 2025 -0.88x
Enterprise Value 2.98M 3.63M 3.26M 2.72M 5.13M 341M 5.29M 35.94M 14.39M 182M 13.64M 13.35M 576M EV / Sales 2024
5.67x
EV / Sales 2025 28.1x
Free-Float
60.59%
Yield 2024 *
-
Yield 2025 -
1 day-7.96%
1 week-7.96%
Current month-7.96%
1 month-7.14%
3 months-46.39%
6 months-56.67%
Current year-62.45%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.018
0.07
1 year 0.02
Extreme 0.018
0.07
3 years 0.02
Extreme 0.018
0.26
5 years 0.02
Extreme 0.018
1.3
10 years 0.02
Extreme 0.018
4
Manager TitleAgeSince
Chief Executive Officer 58 2013-05-31
Director of Finance/CFO 40 2017-05-31
Chief Tech/Sci/R&D Officer 69 2016-11-27
Director TitleAgeSince
Chairman 77 -
Director/Board Member 58 2014-12-31
Director/Board Member 81 2010-05-11
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Issuer sale

Chief Technology Officer

-885,674 0.4051%
9/2/26 Issuer sale

Director

-539,122 0.2466%
9/2/26 Issuer sale

Chief Financial Officer

-1,205,816 0.5515%
Change 5-day change 1-year change 3-year change Capi.($)
-7.96%-7.96%-65.79%-58.40% 5.59M
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average -0.52%+2.13%+43.96%+124.18% 40.58B
Weighted average by Cap. +0.21%+3.40%+53.12%+142.95%

Financials

2024 2025
Net sales 410K 500K 448K 374K 706K 46.96M 728K 4.94M 1.98M 25.05M 1.88M 1.84M 79.18M 173K 211K 189K 158K 297K 19.8M 307K 2.08M 834K 10.56M 791K 774K 33.38M
Net income 7.06M 8.6M 7.71M 6.44M 12.14M 808M 12.52M 85.07M 34.05M 431M 32.3M 31.6M 1.36B -6.73M -8.2M -7.35M -6.14M -11.58M -771M -11.94M -81.12M -32.47M -411M -30.8M -30.14M -1.3B
Net Debt -3.3M -4.02M -3.61M -3.01M -5.68M -378M -5.86M -39.78M -15.93M -202M -15.1M -14.78M -637M -1.6M -1.95M -1.75M -1.46M -2.76M -184M -2.85M -19.34M -7.74M -98M -7.34M -7.18M -310M
Projected Income Statement - Annual - Addex Therapeutics Ltd
Logo Addex Therapeutics Ltd
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Employees
3
Date Price Change Volume
26-11-06 CHF 0.0208 -7.96% 765,087
26-11-05 CHF 0.0226 +2.73% 73,917
26-11-04 CHF 0.0220 +2.80% 1,463,010
26-11-03 CHF 0.0214 -5.31% 211,911
26-11-02 CHF 0.0226 0.00% 58,222
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Addex Therapeutics Ltd

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Addex Therapeutics Ltd
  1. Stock Market
  2. Stocks
  3. ADXN Stock